RNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Avidity Biosciences Inc (RNA) is not a strong buy for a beginner, long-term investor at this moment. Despite bullish moving averages, the technical indicators are mixed, with a neutral RSI and a negative MACD. Insider selling has increased significantly, and the company's financial performance in the latest quarter shows a sharp revenue decline, despite improvements in net income and EPS. Options data indicates a bearish sentiment with a high Open Interest Put-Call Ratio of 7.18. No significant positive catalysts or recent congress trading data are available to support a buy decision.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the MACD is negative and expanding downward (-0.0556), and the RSI is neutral at 45.141. Key support and resistance levels are close to the current pre-market price, suggesting limited immediate upside potential.
NULL identified. No significant news or events directly related to Avidity Biosciences Inc.
Insider selling has increased by 200.63% over the last month. The company's financials show a significant YoY revenue decline (-71.07%) in Q4 2025.
In Q4 2025, revenue dropped by 71.07% YoY to $860,000. However, net income improved by 131.87% YoY to -$237.1 million, and EPS increased by 92.50% YoY to -1.54. Gross margin remained unchanged at 100%.
No recent analyst rating or price target changes are available for Avidity Biosciences Inc.
